Previous Product Image

Oakstone Comprehensive Review of Pain Medicine 2020

40 $

American Society for Clinical Pathology 2020 Virtual Meeting

40 $
Next Product Image

Alzheimer’s Association International Conference 2019

20 $

+ Include: 581 videos, size: 26.2 GB

+ Target Audience: pathologist, neurologist


+ Include: 581 videos, size: 26.2 GB

+ Target Audience: pathologist, neurologist

+ Sample video: contact me for sample video

+ Topics:

02-01-01 – Sleep, Brain, and Cognition.mp4
02-02-01 – Alzheimer’s Disease Blood-Based Biomarkers and AD Control.mp4
03-02-01 – The Epidemiology of Diversity and Dementia.mp4
05-01-01 – Microglia in Neurodegenerative Conditions.mp4
05-02-01 – Precision Medicine, Population Neuroscience and Comprehensive Care Partners to Develop and Deliver Effective Prevention.mp4
DB-01-01 – Temporal Trajectories of In Vivo Tau and Amyloid-á Accumulation in Alzheimer’s Disease.mp4
DB-01-02 – Vascular Risk Factors and Multimodal Neuroimaging Biomarkers Preliminary Analyses from the Multi-Ethnic Study of Atherosclerosis.mp4
DB-01-03 – Global Cortical [F18]Flortaucipir Association with the Top 20 Alzheimer’s Disease Risk Genes.mp4
DB-01-04 – Cerebral Amyloid Angiopathy Is More Severe in Autosomal Dominant AD Cases with Cerebral Microhemorrhages.mp4
DT-01-01 – BAN2401 In Early Alzheimer’s Disease Neurodegeneration Biomarker Analysis From Randomized Phase 2 Study.mp4
DT-01-02 – Continued large amyloid PET reductions at 36 months in the gantenerumab open-label extension studies.mp4
DT-01-03 – Longitudinal amyloid, neurodegeneration and cognition in pre-dementia elderly individuals with different ATN profiles.mp4
DT-01-04 – Diagnostic performance of [18F]RO948 PET in the separation of Alzheimer’s disease.mp4
DT-01-05 – Temporal Lobe Quantitation of Flortaucipir PET Images May Improve Detection of Intermediate Neurofibrillary Tangle Pathology.mp4
DT-01-06 – Association of APOE e2 Genotype with Neuroprotection A Trans-diagnostic Study of 1557 Brains in the NACC v 10 Data Base.mp4
DT-02-01 – Repurposing FDG-PET as a diagnostic tool for Alzheimer’s-related TDP-43-proteinopathy.mp4
DT-02-02 – TOMMORROW Results from a Phase 3 Trial to Delay the Onset of MCI Due to AD and Qualify a Genetic Biomarker Algorithm.mp4
DT-02-03 – Open Label Extension Results from a Phase II III Trial of Intranasal Insulin.mp4
DT-02-04 – A Randomized Double-Blind Placebo-Controlled Phase 2A Clinical Trial of NA-831 in Patients with MCI and early onset of Alzheimer’s disease.mp4
DT-02-05 – A Novel Therapeutic (NTRX-07) Targeting Neuroinflammation in Alzheimer’s disease is Undergoing Phase I trials.mp4
DT-02-06 – A Novel Small Molecule Inhibitor of the Discoidin Domain Receptors (DDR) Reduces Tau and Amyloid-á and Improves Cognition in Models.mp4
EC-01-01 – The Impact of DNA Damage, Transcription Stress and Nutrition on Aging, Protein Aggregation and Neurodegeneration.mp4
EC-01-02 – Transposable Element Activation in Tauopathy.mp4
EC-01-03 – Neuronal and Glial DNA Double Strand Breaks in Early Stages of Alzheimer’s Disease.mp4
EC-01-04 – Age-Related Accumulation of DNA Damage in Microglia and Its Neurotoxic Consequences.mp4
EC-02-01 – A Fundamental Biophysical Process Contributing to Disease Mechanisms Liquid-Liquid Phase Separation of Tau.mp4
EC-02-02 – RNA Metabolism in Stress and Disease RNA Translation, RNA Binding Proteins, RNA Granules.mp4
EC-02-03 – The Role of Stress Granules and RNA Metabolism in the Pathophysiology of Tau.mp4
EC-02-04 – Mechanisms of Accumulation of Pathological TDP-43 In Vivo.mp4
EC-03-01 – Pro Side Presentations (10 minutes each).mp4
EC-04-01 – Panel Discussion.mp4
F1-01-01 – Value of Study Partner Reports to Assess and Predict Cognitive Impairment and Decline.mp4
F1-01-02 – Item-Level Comparison of Participant and Study Partner Report on the Cognitive Function Index By Amyloid PET from the A4 Study.mp4
F1-01-03 – Online Study Partner-Reported Subjective Decline Is Associated with á-Amyloid and Clinical Diagnosis.mp4
F1-01-04 – Why Is the Study Partner Requirement a Barrier to Recruitment in Preclinical Alzheimer’s.mp4
F1-02-01 – Subthreshold Amyloid Accumulation Does It Predict Memory Decline.mp4
F1-02-02 – Biological Consequences of Subthreshold Amyloid Accumulation.mp4
F1-02-03 – Effects of Amyloid Accumulation on Neurocognitive Performance in Healthy Middle-Aged and Older Adults.mp4
F1-02-04 – Multimodal Evidence for Early Amyloid Accumulation.mp4
F1-03-01 – CSF Biomarkers Related to Neurodegeneration As Predictors of Cognitive Progression in MCI and Elderly Controls.mp4
F1-03-02 – The at(N) Framework in the Wisconsin Registry for Alzheimer’s Prevention Evidence from PET Imaging.mp4
F1-03-03 – Distinct Contributions of Baseline and Longitudinal Amyloid PET Measures to Memory.mp4
F1-03-04 – Aá-Positivity Predicts Cognitive Decline but Cognition Also Predicts Progression to Aá-Positivity.mp4
F1-04-01 – Frequency of Subjective Cognitive Decline Criteria in Stage 2 of the New NIA-AA Framework.mp4
F1-04-02 – Harmonizing Subjective Cognitive Decline Measurements across 19 International Cognitive Aging Studies.mp4
F1-04-03 – ATN Biomarker Model As a Determinant of Cognitive Decline and Incident Clinical Progression in Subjective Cognitive Decline.mp4
F1-04-04 – The SCD-Well Randomized Controlled Trial Effects of a Mindfulness-Based Intervention Versus Health Education.mp4
F1-05-01 – Lab-Related Pre-Analytical Factors Influencing Plasma Amyloid Beta Concentrations.mp4
F1-05-02 – Patient-Related Pre-Analytical Factors Influencing Plasma Amyloid Beta Concentrations.mp4
F1-05-03 – The 1946 Cohort – Relationships between Cerebral Amyloid Pathology Using Two Independent Methods for Plasma Amyloid Beta Measurement.mp4
F1-05-04 – The Global Alzheimer’s Association Round Robin Study on Plasma Amyloid Beta Methods.mp4
F1-06-01 – Sleep-Wake Behavior in the 4Repeat Tauopathy- Progressive Supranuclear Palsy.mp4
F1-06-02 – Neurobiological Basis of Sleep and Wake Dysfunction in AD and Other Tauopathies The Role of the Neuromodulatory System.mp4
F1-06-03 – Altered Sleep-Wake Mechanisms in Neurodegenerative Disease Similarities and Difference between Lewy Body Disease and Narcolepsy.mp4
F1-06-04 – Panel Discussion (including the audience brainstorming on the best ways to address gaps).mp4
F1-07-01 – Astroglial and Microglial Modulation of Neural Functions in Models of Alzheimer’s Disease.mp4
F1-07-03 – Alzheimer’s Susceptibility Genes Implicate Microglial Activity.mp4
F1-07-04 – Using Human iPSC Models to Probe TREM2 Function.mp4
F1-08-01 – Ethnic Differences in Cognition and Age in People Diagnosed with Dementia A Study of Electronic.mp4
F1-08-02 – Using Racial Ethnic Comparisons to Evaluate Unmeasured Confounding.mp4
F1-08-03 – The Effect of Ethnicity on the Sensitivity of General Hospital Dementia Records Cohort Study Using English Electronic Health Records.mp4
F1-08-04 – Panel Discussion.mp4
F2-01-01 – Neurodevelopmental Differences and Environmental Insults Inversely Correlate with Age of Onset in Alzheimer’s Disease.mp4
F2-01-03 – Am I the Right Way up Investigating Balance Problems in Posterior Cortical Atrophy.mp4
F2-01-04 – Paradoxical Aging in Alzheimer’s Disease.mp4
F2-02-01 – Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimer’s Disease.mp4
F2-02-02 – Understanding the Role of SORL1 and Endosomal Network Dysfunction in Alzheimer’s Disease.mp4
F2-02-03 – Alzheimer’s Disease Modeling and Drug Screening Using Patients-Derived iPSCs with Different ApoE Genotypes.mp4
F2-02-04 – Targeting Aberrant Cholesterol Metabolism in Alzheimer’s Disease; Drug Discovery in iPSC-Derived Neurons..mp4
F2-03-01 – Clinical Meaningfulness of Short-Term Cognitive Decline on the Preclinical Alzheimer’s ….mp4
F2-03-02 – Optimizing Cognitive Outcomes for Biomarker Positive Individuals at Different Clinical Stages of Alzheimer’s Disease According.mp4
F2-03-03 – Adcoms A Sensitive Measure of Disease Progression in Early AD Supporting Better Development Decisions.mp4
F2-03-04 – Assessing Clinical Meaningfulness of Outcomes in the Alzheimer’s Prevention Initiative Generation Program.mp4
F2-04-01 – Neuropathology of VCID A Classical Landscape.mp4
F2-04-02 – Neuropathology Big Data. It’s All VCID.mp4
F2-04-03 – Digital Molecular Pathology. Axonal Damage and Small Vessel Disease.mp4
F2-04-04 – Leveraging Neuropathology to Integrate with RNA and Other Omics.mp4
F2-05-01 – Sleep Duration over 28 Years and Grey Matter Volumes A Prospective Cohort Study.mp4
F2-05-02 – How Does Sleep-Wake Disturbance Relate to Neuropsychological and Neuroimaging Markers in Older People at Risk for Dementia.mp4
F2-05-03 – Sleep Medication Use and Risk of Dementia in a Biracial Cohort of Older Adults.mp4
F2-05-04 – Slow Wave Sleep Enhancers As a Potential Therapeutic Approach in Delaying Cognitive Decline in Alzheimer’s Disease.mp4
F2-06-01 – Major Differences between the Self-Assembly, Seeding Behavior, and Interaction with Modulators.mp4
F2-06-02 – Trafficking of Tau Oligomers through the Plasma Membranes of Neurons and Astrocytes Is Critical for Their Synaptotoxicity.mp4
F2-06-03 – Amyloid á-Protein Oligomers Promote the Uptake of Tau Fibril Seeds Potentiating ….mp4
F2-06-04 – Polymorphism and Toxic Interactions between Soluble Amyloid Oligomers and Tau.mp4
F2-07-01 – Blood Amyloid-Beta Predicts Amyloid PET Conversion.mp4
F2-07-02 – Recent Findings of Novel Blood Components Amyloid-Beta Measures.mp4
F2-07-03 – Fully Automated Plasma Assays As Screening Tests for Early Alzheimer-Related á-Amyloid.mp4
F2-07-04 – Plasma Amyloid Beta 1-42 and 1-40 Measured By a Novel Simoa Assay As a Diagnostic Tool.mp4
F2-08-01 – Sleep Timing and Risk of Dementia Among Chinese Elderly in an Urban Community.mp4
F2-08-02 – Local Slow Wave Measures during Nrem Slow Wave Sleep Accurately Track á-Amyloid Status.mp4
F2-08-03 – Effect of Sleep on CSF Tau and p-Tau.mp4
F2-08-04 – Obstructive Sleep Apnea, Cognition and AD Neurodegeneration..mp4
F3-01-01 – The Diagnostic Framework for Alzheimer’s Disease.mp4
F3-01-02 – Capturing Cognitive Impairment at the Preclinical Stage of Alzheimer’s Disease Using Digital Technology.mp4
F3-01-03 – The Integrated Cognitive Assessment – Employing Artificial Intelligence for the Detection of Cognitive Impairment.mp4
F3-01-04 – Panel Discussion.mp4
F3-02-01 – The Effect of Race on Driving Performance, Self-Reported and Naturalistic Driving Behavior Among Older Adults.mp4
F3-02-02 – The Stress and Resilience in Dementia (STRIDE) Study Social-Biological Dimensions of ADRD Risk, Disparity, and Resilience.mp4
F3-02-03 – Creating Dementia-Friendly Faith Villages to Support African American Families.mp4
F3-02-04 – It’s Tied to a Purpose A Culturally Celebratory Approach to Motivate Physical and Social Activity Among African Americans.mp4
F3-03-01 – Unveiling the Neural Correlates of Cognitive and Functional Impairments in Ageing and Dementia Relying on Mobile EEG Technologies.mp4
F3-03-02 – Studying the Effects of Repetitive Paired Associative Stimulation on Dlpfc Plasticity.mp4
F3-03-03 – Replicating Lab Electrophysiology with Older Users in the Home, Using Gamified Dry EEG.mp4
F3-03-04 – Exploration of EEG Event-Related Potentials in a Memory Disorders Clinic.mp4
F3-04-01 – Barriers and Facilitators for Retaining Independence at Home from a UK Multi- Stakeholder Perspective.mp4
F3-04-02 – Inequalities in Care Provision for People with Dementia from Different Ethnic Minority Groups.mp4
F3-04-03 – Co-Designing a Training Programme for Paid Home Carers to Deliver Dementia Specific Care to People at Home.mp4
F3-04-04 – Stakeholder Perspectives on How the Home Care Sector Can Support People to Live Well with Dementia..mp4
F3-05-01 – Vascular Cognitive Disorders in L M I Cs Challenges and Opportunities in Studying Diverse Populations.mp4
F3-05-02 – Vascular Risk Factors for a D R D in Latin America A Focus on the Caribbean.mp4
F3-05-03 – Vascular Risk Factors and Multimodal Neuroimaging Biomarkers Preliminary Analyses.mp4
F3-05-04 – White Matter Hyperintensities and Cognition The Moderating Role of Quality of Education in a Multiracial Community Sample.mp4
F4-01-01 – Plasma Test for Amyloid Risk Screening The C2N sponsored PARIS Add-on Study to IDEAS.mp4
F4-01-02 – Increasing the Impact of the Ideas Study Using Brain Health Registry Online Data Collection.mp4
F4-01-03 – Caregivers’ Reactions and Experiences Imaging Dementia-Evidence for Amyloid Scanning (CARE IDEAS).mp4
F4-01-04 – Amyloid Neuroimaging and Genetics Initiative A Resource for Investigators.mp4
F4-01-05 – Racial and Ethnic Differences in Amyloid PET Positivity in the IDEAS Study.mp4
F4-02-01 – Trials and Tribulations of Tau PET Imaging.mp4
F4-02-03 – Tau Fluid Biomarkers State-of-the-Art and Novel Findings in AD and Primary Tauopathies.mp4
F4-02-04 – CSF and PET Measures for Tau in Different Stages of Alzheimer’s Disease.mp4
F4-03-01 – Neuropathological Features Underlying Ante-Mortem Cholinergic Basal Forebrain and Medial ….mp4
F4-03-02 – Neuropathological Substrate of Imaging Biomarkers – Validating Neuroimaging Biomarkers in AD.mp4
F4-03-03 – Selectivity of PET Amyloid Imaging Ligands in the Alzheimer’s Disease Neuropathology Spectrum.mp4
F4-03-04 – Autopsy Validation of Amyloid and Tau PET in Clinical Populations.mp4
F4-04-01 – Trial Design, Data Sharing Risk Mitigation, and Baseline Clinical and Cognitive Data from the API.mp4
F4-04-02 – Age-Related Changes in Baseline Cognitive Measures in Unimpaired PSEN1- E280A.mp4
F4-04-03 – Relationships between Baseline Brain Imaging Biomarker Measurements.mp4
F4-04-04 – Association between Cerebral Amyloidosis and Worse Cognitive Performance.mp4
F4-05-02 – Comparison of Variables Associated with CSF Neurofilament, Total-Tau, and Neurogranin in a Community-Based Study.mp4
F4-05-03 – Blood Neurofilament Light (NFL) – a Sensitive but Slow-Release Biomarker.mp4
F4-05-04 – Serum Neurofilaments As Therapy Response Markers in Neurodegenerative Diseases.mp4
F4-06-01 – The Rowland Universal Dementia Assessment Scale A Cross-Cultural Screening Measure for Dementia Clinical Trials.mp4
F4-06-02 – Building Cognitive Reserve in Resource-Limited Settings Evidence from the Health and ….mp4
F4-06-03 – Staging of Cognitive Impairment and Dementia in Low-Educated Elderly.mp4
F4-06-04 – Detecting Dementia in Older, Ethnically Diverse Residents in Rural Subsidized Housing.mp4
F5-01-01 – The Role of Lipid Mediators in Neuroinflammation and Preoperative Neurocognitive Disorders.mp4
F5-01-03 – Neurofilament Light in a Mexican American Cohort.mp4
F5-01-04 – Inflammation As a Potential Shared Mechanism for Postoperative Delirium and Long-Term Cognitive Decline in Older Adults Undergoing.mp4
F5-02-01 – The Interaction of Genetic Admixture and ApoE4. Implications for Cognitive Decline in Alzheimer Disease..mp4
F5-02-02 – Higher Literacy Associates with Better Brain Structure and Cognition in Middle-Aged Individuals.mp4
F5-02-03 – Factors Impacting Loss-to-Follow-up from a Memory Care Center A Study of Potential Palliative Care Needs.mp4
F5-02-04 – Advanced Directive and POLST Utilization in Decedents with Dementia Previously Seen at a Memory Center.mp4
FTS1-01-01 – Introduction to LATE.mp4
FTS1-01-02 – The Pathology of LATE.mp4
FTS1-01-03 – Public Health Impact and Cognition Associated with LATE Neuropathology.mp4
FTS1-01-04 – LATE Biomarkers and Impact on Alzheimer’s Prevention and Treatment Trials.mp4
FTS1-01-05 – Panel Discussion LATE into the World of Alzheimer’s Dementia Nomenclature to Advance Science amidst Multiple Stakeholders.mp4
FTS2-01-01 – Panel Presentation.mp4
FTS3-01-01 – Umibecestat (CNP520) Is Not Associated with Changes in Hippocampal Morphology.mp4
FTS3-01-02 – Subgroup Populations in Amaranth, a Randomized Phase 23 Study in Early Alzheimer’s Disease with Lanabecestat.mp4
FTS3-01-03 – Performance on Exploratory Efficacy Variables in Amaranth, a Randomized Phase 23.mp4
FTS3-01-04 – Final Efficacy, Safety and Biomarker Results of the Phase 2b3 .mp4
FTS3-01-05 – Further Analyses of Cognitive Outcomes in the Apecs Phase-3 Trial of Verubecestat in Prodromal AD.mp4
FTS3-01-06 – Current Update on Elenbecestat in Alzheimer”s Disease.mp4
FTS3-01-07 – Panel Discussion.mp4
FTS5-01-02 – Correlating Cognitive Outcomes with Patient Specific Biomarkers in Alzheimer’s Disease.mp4
FTS5-01-03 – A Pharmacokinetic Pharmacodynamic Evaluation of Imaging Biomarkers of Alzheimer”s Disease.mp4
FTS5-01-04 – The Amyloid Hypothesis Latest Update in the Context of Recent Trial Evidence.mp4
IC-01-01 – [Alzheimer’s Imaging Consortium] Plenary Session What Have We Learned.mp4
IC-02-01 – Grey Matter Connectivity Trajectories across the Alzheimer’s Disease Continuum and Associations with Cognitive Decline.mp4
IC-02-02 – Longitudinal Evaluation of Tau Propagation Using [18f]MK-6240.mp4
IC-02-03 – Mild Cognitive Impairment Progressing to Dementia with Lewy Bodies Regional Atrophy Rates and Relationship to AV-1451 Uptake.mp4
IC-02-04 – Novel Measures of Longitudinal Change in Medial Temporal Lobe Subregions Discriminate Preclinical Alzheimer’s Disease.mp4
IC-02-05 – Gender Differences in the Association between Longitudinal Brain Changes and Baseline Levels of CSF.mp4
IC-03-01 – Plenary Session Preclinical Cognitive Decline Is Related to Tau and Amyloid Imaging Profiles in a Risk-Enriched Cohort.mp4
IC-04-01 – The Search for Pathologically Valid Imaging Biomarkers – AD Pathology Comes Not Alone.mp4
IC-04-02 – Ante-Mortem Volume Loss Mirrors TDP43 Staging in Non-FTLD Older Adults.mp4
IC-04-03 – Utility of MRI in Detection of Atrophy in Hippocampal Sclerosis of Aging.mp4
IC-04-04 – Iron, Neurodegeneration, Tau, and Amyloid in Patients with Alzheimer’s Disease..mp4
IC-04-05 – Cross-Sectional and Longitudinal Medial Temporal Lobe Subregional Atrophy in Suspected ….mp4
IC-05-01 – Debate MRI Versus PET Which Imaging Modality Provides the Best Biomarker and for Which Purpose.mp4
IC-06-01 – Assessment of Longitudinal Amyloid Load Change in Down Syndrome.mp4
IC-06-02 – Associations between Aá and Tau in Adults with Down Syndrome.mp4
IC-06-03 – Spatial Associations of Aá with Tau Deposition in Down Syndrome.mp4
IC-06-04 – Sleep, Cognition, and á-Amyloid in Adults with Down Syndrome.mp4
IC-06-05 – Baseline Amyloid (18F-AV-45 PET) Distributions By Consensus Diagnosis from the Biomarkers.mp4
IC-07-01 – Functional Brain Architecture Predicts Longitudinal Tau Spreading in Alzheimer’s Disease.mp4
IC-07-02 – What Can Structural MRI Tell about aTN Staging.mp4
IC-07-03 – Biomarkers for Capturing Amyloid Independent Effects of Vascular Health on Cognitive Decline.mp4
IC-07-04 – A Topographic Imaging Biomarker of TDP43 Pathology in Amnestic Dementia Based on Autopsy-Derived FDG-PET Patterns.mp4
IS-01 – ISTAART Student Workshop Series Final Title TBD.mp4
IS-02 – ISTAART Student Workshop Series Final Title TBD.mp4
IS-03 – ISTAART Student Workshop Series Final Title TBD.mp4
O1-01-01 – Integrative Proteomics Links Cerebrospinal Fluid Biomarkers to Pathological Networks in Alzheimer’s Disease Brain.mp4
O1-01-02 – Tau Phosphorylation Rates Change from Brain to Cerebrospinal Fluid and Are Differentially Affected By Alzheimer Disease.mp4
O1-01-03 – Plasma Aá42 Aá40 Predicts Hippocampal Atrophy.mp4
O1-01-04 – Identification and Biological Characterization of Extracellular Vesicle Proteins for Propagation and Spread of Tau.mp4
O1-01-05 – Proteomic Assessment of Synapses with Rich Associated Clinical Data Highlight Potential Targets.mp4
O1-01-06 – Neuron-Glia Interaction Markers in Predementia Alzheimer’s Disease.mp4
O1-02-01 – Self-Reported Hearing and Vision Impairment Predicts Dementia in the Oldest Old Pooled Analysis.mp4
O1-02-02 – The Impact of Hearing Loss and Sensory Intervention on the Risk of Progression to Dementia in Mild Cognitive Impairment Cases.mp4
O1-02-03 – Age-Related Hearing Loss and Cognitive Decline in the General Population.mp4
O1-02-04 – Failure to Identify Particular Odours Predicts Future Dementia and Mortality.mp4
O1-02-05 – Dual Sensory Impairment in Older Adults and Risk of Dementia and Alzheimer’s Disease.mp4
O1-02-06 – Association between the Olfactory Identification Ability and Cognitive Function in Non-Demented Elderly.mp4
O1-03-01 – Misfolding and Early Aggregation of Amyloid á42 Protein Critical Role of Membranes.mp4
O1-03-02 – Mechanistic Mathematical Model of the Impact of Anti-Amyloid Beta Drugs and BACE Inhibitors in Alzheimer’s Disease..mp4
O1-03-03 – Predicting Brain Amyloidosis Using Peripheral Blood-Based Gene Expression and Early Stage Neurodegeneration Biomarkers.mp4
O1-03-04 – Cortical Neurons and Cerebral Organoids from APP and PSEN1 Mutation Carriers Reveal ….mp4
O1-03-05 – Induction of Different Brain Pathology in Mice Treated with Two Misfolded Aá Conformers.mp4
O1-03-06 – Pyroglutamation of Aáx-42 and Aá1-40 Deposition Underlie Amyloid Plaque Polymorphism.mp4
O1-04-01 – A Topographic Imaging Biomarker of TDP43 Pathology in Amnestic Dementia Based on Autopsy-Derived FDG-PET Patterns.mp4
O1-04-02 – Early and Late-Onset Alzheimer’s Disease and Suspected Non-Alzheimer Pathophysiology within the aTN Framework.mp4
O1-04-03 – Visually-Rated Structural MRI Profiles in Neuropathologically-Confirmed Chronic Traumatic Encephalopathy.mp4
O1-04-04 – Metabolic Brain Pattern of Creutzfeldt-Jakob Disease and Its Biological Significance.mp4
O1-04-05 – Pathologic Associations of FDG PET in Lewy Body Disease.mp4
O1-04-06 – Cognitive Impairment in in Older Adults with MCI Due to SNAP May be Partially Attributable to Comorbid Conditions.mp4
O1-05-01 – Public Involvement in Research Collaborations in Dementia Care.mp4
O1-05-02 – Nothing about Us without Us Creating the First Canadian Charter of Rights for People with Dementia.mp4
O1-05-03 – Wrap Around Services to Older Adults with Dementia Collaboration, Education, and Prevention.mp4
O1-05-04 – Reaching Individuals Living with Alzheimer’s Disease or Related Dementias from Minority Population.mp4
O1-05-05 – Promoting Dementia Awareness in African American Communities Impact of the Dementia Caring Community Outreach Model.mp4
O1-05-06 – Aging with Pride, IDEA Lessons Learned from the First Tested Clinical Intervention Addressing Dementia.mp4
O1-06-01 – Impact of Healthy Lifestyle Factors on the Risk of Alzheimer’s Dementia; Findings from Two Prospective Cohort Studies.mp4
O1-06-02 – Genetic Risk, Lifestyle and Dementia.mp4
O1-06-03 – Characterization of Cognitive Performance, Gray Matter Volume and White Matter Microstructure.mp4
O1-06-04 – Association between Hypertension and Alzheimer’s Disease and Related Causes of Dementia A Pathways Analysis in the Memento Cohort.mp4
O1-06-05 – Higher Education Provides Resilience Against Deteriorative Effects of Higher Middle Age Body Mass Index on Old Age Cognitive Functioning.mp4
O1-06-06 – The Compensatory Role of Physical Activity on the Association between the ….mp4
O1-07-01 – Longitudinal Evaluation of the Natural History of Aá in Plasma and Brain.mp4
O1-07-02 – Longitudinal Associations between Plasma Nfl and Voxel-Based Morphometry in Alzheimers Disease.mp4
O1-07-02 – Longitudinal Associations between Plasma Nfl and Voxel-Based Morphometry in Alzheimer’s Disease.mp4
O1-07-03 – Longitudinal Plasma Neurofilament Light Is Associated with Rates of Regional Brain Atrophy in Alzheimer’s Disease.mp4
O1-07-04 – CSF Biomarkers of Amyloid, Tau and Synaptic Damage (Neurogranin, SNAP25) and Interneuron-Dependent.mp4
O1-07-05 – Longitudinal Effect of Biological Variables on Plasma NFL and t-Tau Concentrations on Subjective Memory Complainers.mp4
O1-07-06 – Prevalence and Longitudinal Clinical Outcomes of Alzheimer’s ATN Biomarker Profiles A Longitudinal Study.mp4
O1-08-01 – Therapeutic Targeting of TREM2 By an Activating Antibody Ameliorates Amyloid-Beta Deposition.mp4
O1-08-02 – Development of TREM2 Agonistic Antibodies to Treat Alzheimer’s Disease.mp4
O1-08-03 – Targeting NLRP3 Inflammasome with a Novel Inhibitor for Alzheimer’s Disease.mp4
O1-08-04 – Preclinical Development of TREM2 Agonist Antibody (AL002) in Cynomolgus Monkeys.mp4
O1-08-05 – Anti-Inflammatory Effects of SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor in Neurodegenerative Mouse Models.mp4
O1-09-01 – Estimating Years from Clinical Symptom Onset for Sporadic Alzheimer Disease How Far Are We.mp4
O1-09-02 – Two-Period Linear Mixed Effects Primary Analysis Model for Clinical Trials with Run-in Data for Alzheimer Disease.mp4
O1-09-03 – Sex Is Not an Important Predictor of Change in Alzheimer’s Clinical Trial Outcomes.mp4
O1-09-04 – Applying Polygenic Hazard Scores to Enrich Clinical Trial Study Populations of Those at Risk of Alzheimer’s Disease Dementia (ADD).mp4
O1-09-05 – Sexual Dimorphism in Plasma Beta-Secretase 1 Concentrationsin Cognitively Normal Individuals at Risk for AD.mp4
O1-09-06 – Addressing Polypharmacy Issues in an Elderly Population with Cognitive Impairment, Using a Precision-Medicine Platform.mp4
O1-10-01 – Assessing Global and Regional Aá-Amyloid Deposition in the Brain with Multiple Aá-Tracers Using the Centiloid Scale.mp4
O1-10-02 – Longitudinal Analysis of Multivariate Patterns of Amyloid Deposition Reveals Consistent Stages of Amyloidosis across Studies and Tracers.mp4
O1-10-03 – Anatomical Staging of Beta-Amyloid Accumulation Based on Longitudinal Assessment of Globally PIB Negative Adults.mp4
O1-10-04 – Centiloid Cut-Off Values for Optimal Agreement between Amyloid PET and CSF Core AD Biomarkers.mp4
O1-10-05 – Longitudinal Investigation of Concordant and Discordant Amyloid CSFPET Biomarkers Reveals CSF-First.mp4
O1-10-06 – Centiloid Scale in Practice Effect of Different Suvr Reference Regions and Comparison of Centiloid Cut-Offs.mp4
O1-11-01 – Carer’s Appraisal of People with Dementia’s Performance of Daily Tasks What Is the Role of the Carer Management Style.mp4
O1-11-02 – Estimated Impact of Diagnostic Tools for Primary Care Settings on Demand for Specialist Visits for Patients with Prodromal Alzheimer’s Disease.mp4
O1-11-03 – Development and Validation of the Electronic Health Record Risk of Alzheimer’s and Dementia Assessment Rule (eRADAR).mp4
O1-11-04 – The Acceptance of Using Virtual Reality in a Cognitive Stimulation Activity in Older Adults. a Multicenter Randomized Controlled Trial..mp4
O1-11-05 – Effects of a Distraction Method Using a Social Robot on Pain and Anxiety Management in Major Neurocognitive Disorders.mp4
O1-11-06 – High Intensity Telemedicine Reduces Emergency Department Use By Older Adults with Dementia in Senior Living Communities.mp4
O2-01-01 – Brooklyn Cognitive Impairments in Health Disparities Pilot Study.mp4
O2-01-02 – Caregiver Distress from Behavioral Disturbances in Persons with Autosomal Dominant Alzheimer’s Disease Mutations.mp4
O2-01-03 – Abide Delphi Study Topics to Discuss in Diagnostic Consultations in Memory Clinics.mp4
O2-01-04 – Individualized Non-Pharmacological Services Integrating Geriatric Health and Technology (INSIGHT).mp4
O2-01-05 – Designing a Better Visit Touch Screen Apps for People Living with Dementia and Their Visitors.mp4
O2-01-06 – New York State’s Public Health Approach to Alzheimer’s Disease.mp4
O2-02-01 – Different CSF Total and Phosphorylated Tau, but Not Aá, in Older and Younger African Americans and Whites.mp4
O2-02-02 – Comparison of Cognitive, Biomarker and Neuroimaging Characteristics of T+N+ Patients.mp4
O2-02-03 – Stepwise Patient Selection for Amyloid Measurements.mp4
O2-02-04 – CSF Biomarkers in Down Syndrome.mp4
O2-02-05 – Predicting Brain Age As a Biomarker for Risk of Dementia.mp4
O2-02-06 – Cerebrospinal Fluid Based Biomarker Evidence of Amyloidogenesis in Dementia with Lewy Bodies Depends upon ApoE-e4 Carrier Status.mp4
O2-03-01 – Amyloidosis Induces Early Metabolic Reorganization.mp4
O2-03-02 – Derivation and Potential Utility of an Aá PET Imaging Based Weighting Factor for Estimation of Aá Load.mp4
O2-03-03 – Predictors of á-Amyloid Positivity in Cognitively Impaired Patients. Data from the.mp4
O2-03-04 – Defining Amyloid PET Positivity – What If the Coin Had More Than 2 Sides.mp4
O2-03-05 – Prevalence of Clinically Vs. Biologically Defined Alzheimer’s Spectrum Entities Using the National Institute on Aging.mp4
O2-03-06 – Heterogeneity of Amyloid Deposition Pattern Among Amyloid-Positive Cognitively Impaired Individuals.mp4
O2-04-01 – The Role of Astrocytic a7 Nicotinic Acetylcholine Receptors in Neuroinflammation-Mediated Cognitive Impairment.mp4
O2-04-02 – Visualizing Brain Astrocytes – Characterization of 3H-BU99008, an Imidazoline 2 Receptor Ligand, in Human AD Brain.mp4
O2-04-03 – Astrocytosis and Microgliosis Are Early Features of Conditional Mouse Models of ….mp4
O2-04-04 – A Novel Transgenic Rat Model for Mixed Dementia.mp4
O2-04-05 – Predictive Network Analysis Identifies Microglial-Specific Therapeutic Targets for Phagosome.mp4
O2-04-06 – Polymicrobial Infection Exacerbates Neuroinflammation and Worsens Alzheimer’s Associated.mp4
O2-05-01 – Cerebrospinal Fluid Synaptic Vesicle Glycoprotein 2A in Alzheimer’s Disease.mp4
O2-05-02 – Combining Omics and Cognitive Tests Data from the Insight Pre-AD Study, Artificial Intelligence Technology.mp4
O2-05-03 – Characterization and Transfer of a Novel Plasma Aá1-42Aá1-40 Simoa Assay for ….mp4
O2-05-04 – Plasma pTau181 Levels Reflect [18F]AV1451 Tau PET Uptake across the Tauopathy Spectrum.mp4
O2-05-05 – Correlation of CSF Phospholipids and Alzheimer’s Disease Neuropathology.mp4
O2-05-06 – Diagnosing Alzheimer’s Disease through Detection of Tau Protein in Human Blood Using Ultrasensitive.mp4
O2-06-01 – How Do People with Young-Onset Dementia and Their Family Make Decisions and Plan for the Future in Relation.mp4
O2-06-02 – Financial, Legal, and Social Decision-Making in Early-Onset Alzheimer’s Disease.mp4
O2-06-03 – Patterns of Dyadic Appraisal of African American Persons with Dementia Decision-Making and Quality of Life.mp4
O2-06-04 – Ethical Issues Raised By the Introduction of Artificial Companions to Older Adults with Cognitive Impairment A Call for Empowerment.mp4
O2-06-05 – Preliminary Results from the Study of Knowledge and Reactions to Apoe Testing (SOKRATES 2).mp4
O2-07-01 – Sleep Quality and Beta-Amyloid Deposition in Recently Menopausal Women Participating in the Kronos Early Estrogen Prevention Study (KEEPS).mp4
O2-07-03 – Differential Influence of Aging and Alzheimer’s Disease on Sleep and Rest-Activity Rhythms over Entire Adult Life.mp4
O2-07-04 – High Compliance, Continuous Long-Term Home Monitoring of Sleep Activity in Diverse Populations Differentiates Lower.mp4
O2-07-05 – Obstructive Sleep Apnea Severity and Brain Integrity in Ageing A Multimodal ….mp4
O2-07-06 – Sleep-Wake Cycle and 2-Year Changes of Alzheimer’s Disease Neuroimaging Biomarkers and Cognition.mp4
O2-08-01 – Ante-Mortem Volume Loss Mirrors TDP43 Staging in Non-FTLD Older Adults.mp4
O2-08-02 – Early Life Foreign Language Instruction and Late Life Amyloid and Tau Deposition.mp4
O2-08-03 – Long-Term Exposure to Air Pollution and Dementia A Large Clinicopathological Study.mp4
O2-08-04 – Phenotypic Heterogeneity in Familial Alzheimer’s Disease and Associations with Cerebral Amyloid Angiopathy.mp4
O2-08-05 – Pathological Drivers of Neurodegeneration in Suspected Non-Alzheimer’s Pathophysiology.mp4
O2-08-06 – CA2 Neurofibrillary Degeneration and Asymmetry in Primary Age-Related Tauopathy.mp4
O2-09-01 – The Natural History of Alzheimer’s Disease in Down Syndrome.mp4
O2-09-02 – Biphasic Trajectory of Changes for Cortical Thickness and Cortical Mean Diffusivity in Autosomal Dominant Alzheimer’s Disease.mp4
O2-09-03 – Effects of Gene Mutation and Disease Progression on the Structure and Function of Three Cortico-Subcortical Neural Circuits.mp4
O2-09-04 – Single-Subject Grey Matter Networks Deteriorate 12 Years before Dementia.mp4
O2-09-05 – Longitudinal F-AV-1451 Tau PET in Familial Alzheimer’s Disease.mp4
O2-09-06 – Trajectory of Lobar Atrophy in Asymptomatic and Symptomatic Grn Mutation Carriers.mp4
O2-10-01 – Stop-Gain and Non-Synonymous Variants in Novel Genes of an Immune Co-Regulatory Network.mp4
O2-10-02 – Whole Exome Sequencing Analysis in Early Onset Alzheimer Reveals Novel Candidate Genes.mp4
O2-10-03 – Leveraging Tissue Specific Gene Expression Regulation to Identify Genes Associated with Alzheimer’s Disease.mp4
O2-10-04 – Mitochondrial Variants and Haplogroups Associated with Late-Onset Alzheimer’s Disease Identified By Whole Exome Sequencing.mp4
O2-10-05 – Meta-Analysis Employing the African Genome Resources Panel Identifies Novel Alzheimer.mp4
O2-10-06 – Genome-Wide Meta-Analysis of Late-Onset Alzheimer’s Disease Using Rare Variant Imputation in 64,859.mp4
O2-11-01 – Cross-Sectional Associations between CSF Biomarkers of Amyloid and Tau with Neuropsychiatric Symptoms.mp4
O2-11-02 – Neuropsychiatric and Cognitive Symptoms in Alzheimer’s Disease A Study in AD Biomarker Confirmed Patients across the Clinical Spectrum.mp4
O2-11-03 – Behavioral Symptoms Are a Harbinger of Further Cognitive Decline in a 2 Year Longitudinal Study .mp4
O2-11-04 – Towards a Multidimensional Assessment of Apathy in Neurocognitive Disorders.mp4
O2-11-05 – Mild Behavioral Impairment Is Associated with á-Amyloid but Not with Tau in Cognitively.mp4
O2-11-06 – The Course of Apathy in People with Dementia.mp4
O3-01-01 – Interaction between Obesity, Brain HDL, and ApoE4 Genotype in Cerebral Amyloidosis.mp4
O3-01-02 – Chimera Repetitive Mild Traumatic Brain Injury Induces Chronic Behavioral and Neuropathological Phenotypes.mp4
O3-01-04 – Mechanism Securing ‘-Secretase-APP Aá’ Complexes and Regulating Aá Length.mp4
O3-01-05 – Mir-204 Attenuates Memory Deficits in a Mouse Model of Alzheimer’s Disease.mp4
O3-01-06 – Strategy for Development of RNA Aptamers That Target the Toxic Oligomers of Aá42.mp4
O3-02-01 – Apoe-e4 Allelic Load Modulates the Association between CSF Beta-Amyloid and Gray Matter Volume in Cognitively.mp4
O3-02-02 – Amyloid PET, Tau PET, and MRI Measurements in Cognitively Unimpaired Persons with Two, One, & No Copies of the APOE4 Allele.mp4
O3-02-03 – Association between Apoe Isoform and 18-Month Tau Accumulation.mp4
O3-02-04 – APOE Affect the Network Architecture of the Resting Brain in Individuals at Risk for AD.mp4
O3-02-05 – The Association between Apoe 4 and Age-Related Resting State Functional Connectivity in a Community-Base.mp4
O3-02-06 – Cognitively Normal Apoe-e2 Homozygotes Display Greater Hippocampi An Unbiased Voxel-Based Analysis.mp4
O3-03-01 – The Sequence and Timing of Preclinical Cognitive Decline in Autosomal Dominant Alzheimer’s Disease.mp4
O3-03-03 – Change in Cognition Is Correlated with Change in Brain Volumes in Cognitively Normal Older Adults.mp4
O3-03-04 – Divergent Associations between Life Course Cognitive Trajectories and Brain Pathologies Findings from the 1946 British Birth Cohort.mp4
O3-03-05 – Proper Nouns from Story Recall Are Associated with Beta-Amyloid in Cognitively Unimpaired Adults.mp4
O3-03-06 – Biomarkers and Neuropsychological Measures Differentially Predict Risk of Alzheimer’s Dementia for Men and Women.mp4
O3-04-01 – Biomarkers for Capturing Amyloid Independent Effects of Vascular Health on Cognitive Decline.mp4
O3-04-02 – Microvascular Signature of Preclinical Alzheimer’s Disease in a Longitudinal Cohort.mp4
O3-04-03 – MRI Measures of Neurodegeneration and Vascular Injury, but Not Amyloid Status Predict Cognitive Decline.mp4
O3-04-04 – The Impact of Cerebrovascular Disease on the ATN Profile of Young Cognitively Impaired Patients.mp4
O3-04-05 – Distinctive Effects of Amyloid and Tau on Cognitive Decline According to Cerebrovascular Disease Burden.mp4
O3-04-06 – Comorbid Amyloid-á Pathology Affects Neuropsychiatric, Neuropsychological.mp4
O3-05-01 – Genetic Predisposition, Modifiable Risk Factor Profile, and Long-Term Dementia Risk in the General Population.mp4
O3-05-02 – Current and Past Physical Activity and Risk of Alzheimer’s Disease in Older Adults.mp4
O3-05-03 – The Relationship between Adherence to Australian Dietary Guidelines and Brain Health in Older People with and without Type 2 Diabetes.mp4
O3-05-04 – Associations of the Lifestyle for Brain Health (LIBRA) Index with Structural Brain Changes and Cognition Results.mp4
O3-05-05 – The Prevalence and Attributable Risk of Common Important Risk Factors to Inform Strategies for the Population-Based.mp4
O3-05-06 – Global Council on Brain Health Lifestyle Recommendations for Adults 50+.mp4
O3-06-01 – NIH Toolbox Cognition Tablet Battery in Identification of Early Cognitive Impairment.mp4
O3-06-02 – Cognitive and Motor Function in Aging Community-Dwelling Individuals The Rotterdam Study.mp4
O3-06-03 – Awareness of Memory Decline in Asymptomatic at Risk for Alzheimer’s Disease The Meta-Memory Ratio..mp4
O3-06-04 – Evolution and Pathological Basis of Altered Memory Self-Awareness in Cognitively Normal Older Adults.mp4
O3-06-05 – Multiple Memory Tests Substantially Improve Longitudinal Prediction of Progression to Mild Cognitive Impairment.mp4
O3-06-06 – Large-Scale Remote Assessment of Verbal Cognitive Function Using Automatic Speech Recognition..mp4
O3-07-01 – Transmission of Tauopathy Strains Is Independent of Their Isoform Composition.mp4
O3-07-02 – Lysosomal Dysfunction in Stem Cell Models of Tauopathy.mp4
O3-07-03 – Decreased White Matter Fiber Cross-Section Is Associated to Normal Aging and Higher Tau Deposition Independently of Amyloid.mp4
O3-07-04 – Impaired Neural Code of Spatial Information in a Mouse Model of Tau Pathology.mp4
O3-07-05 – Amyloid-Dependent and Amyloid-Independent Effects of Tau on Clinical Status.mp4
O3-07-06 – In Vivo Network Models Highlight Sex-Specific Differences in the Spread of Tau Pathology across Brain Regions.mp4
O3-08-01 – Phenotypes of Cardiovascular Damage and the Association with Cognitive Decline Among Older Adults A Latent Class Analysis Approach.mp4
O3-08-02 – Cardiovascular Risk Factors across the Lifecourse & Cognitive Decline A Pooled Cohort Study.mp4
O3-08-03 – Unsupervised Machine-Learning for Tracking High Likelihood of Dementia in 9 Population-Based Surveys.mp4
O3-08-04 – A Mediation Analysis of the Relationship between White Matter Hyperintensities, CSF Biomarkers.mp4
O3-08-05 – Lifecourse Work-Family Demands and Late-Life Memory Decline Among U.S. Women.mp4
O3-08-06 – Using Genetic Information to Identify Earliest Manifestations of Alzheimer’s Disease.mp4
O3-09-01 – Protective Effect of Physical Activity on Longitudinal Cognitive Decline.mp4
O3-09-02 – White Matter Hyperintensities in Relation to Patterns of Accelerated Brain Aging.mp4
O3-09-03 – Relationship between Midlife Factors and Multimodal Imaging .mp4
O3-09-04 – Age, á-Amyloid and Cognition Selectively Influence Hippocampal Subfield Volume.mp4
O3-09-06 – Cognitive and Brain Resilience to Tau Pathology in Alzheimer’s Disease.mp4
O3-10-01 – Correlation between Amyloid Reduction and Clinical Outcomes Exploratory Analyses.mp4
O3-10-02 – Verubecestat-Induced Brain Volume Loss Occurs Rapidly and Only in Amyloid-Enriched Brain Regions in EPOCH.mp4
O3-10-03 – The Role of Capillary Angiopathy and Aquaporin 4 in ARIA Induced By Aá Immunization.mp4
O3-10-04 – A Statistical Translation of the Public BAN2401 Study Results from a Bayesian to a Traditional Framework.mp4
O3-10-05 – Modulation of microRNA Pathways By Gemfibrozil in Predementia Alzheimer Disease.mp4
O3-11-01 – Informant Ratings, but Not Self-Reports, of Cognitive Decline Predict Amyloid PET Positivity.mp4
O3-11-02 – Latent Class Analysis Identifies Functional Decline with Amsterdam Iadl in Pre-Clinical Alzheimer’s Disease.mp4
O3-11-03 – Subjective Memory Complaint Is Not Associated with Grey-Matter Volume and Brain Activation.mp4
O3-11-04 – Age-Anchoring SCD to Optimize Its Association with CSF AD Biomarkers.mp4
O3-11-05 – Disentangling the Temporal Sequence of Subjective Cognitive Decline, Depressive Symptoms.mp4
O3-11-06 – Subjective Cognitive Decline in and across International Cohort Studies of Ageing The Cosmic Collaboration.mp4
O3-12-01 – Association between Serum Neurofilament Light and Established White.mp4
O3-12-02 – Plasma Amyloid, Inflammatory Markers, and Time to Dementia in the Ginkgo Evaluation of Memory Study.mp4
O3-12-03 – The CSF Synaptic Biomarker BACE1 Correlates with Cognition in MCI and Alzheirmer Disease.mp4
O3-12-04 – Blood-Based Neuro-Inflammation Biomarkers Differentiate Patterns of Vascular Brain Injury.mp4
O3-12-05 – Increased CSF Soluble TREM2 Is Associated with Ameliorated Longitudinal Cognitive and Clinical Decline.mp4
O3-12-06 – Novel CSF Protein Biomarkers for Specific and Differential Diagnosis of AD..mp4
O3-13-01 – Highly Penetrant Late-Onset Alzheimer Disease Variants in NOTCH3 in Ashkenazi Jews.mp4
O3-13-02 – Genome-Wide Linkage Analysis of African-American Alzheimer Disease Families.mp4
O3-13-03 – The Role of ZCWPW1 Susceptibility Locus Rare Variants in Alzheimer’s Disease.mp4
O3-13-04 – Genetic Variants in Alzheimer’s Disease-Associated Regions Have Different Effects.mp4
O3-13-05 – Genetic Study of 404 Pedigrees with Familial Alzheimer’s Disease in China.mp4
O3-13-06 – The MS4A Gene Cluster Is a Key Modulator of Soluble TREM2 and Alzheimer Disease Risk.mp4
O3-14-01 – Increased Adherence to Brain-Healthy Behaviors Is Associated with Improved Quality of Life in Older Adults.mp4
O3-14-02 – The Promoting Activity, Independence and Stability in Early Dementia (PrAISED) Research Programme.mp4
O3-14-03 – A Scoping Review of Behaviour Change Theories in Adults without Dementia to Develop.mp4
O3-14-04 – A Pilot Cluster RCT to Test the Preliminary Efficacy of an Alzheimer’s Family Caregiver Intervention in Hanoi, Vietnam.mp4
O3-14-05 – Our Family Journey Program- an Evidence-Based, Skills Building Mental Health .mp4
O4-01-01 – Inhibiting Amyloid-Beta Cytotoxicity through Its Interaction with the Cell.mp4
O4-01-02 – Structure Based Inhibitors of Amyloid Beta Core Suggest a Common Interface with Tau.mp4
O4-01-03 – Mechanisms of Inhibitors That Block Seeding By Tau from Human Tauopathies.mp4
O4-01-04 – Polymorphism and Toxic Interactions between Soluble Amyloid Oligomers and Tau.mp4
O4-01-05 – Comparative Prionoid and Strain Properties of Tau and Synuclein.mp4
O4-01-06 – Secernin-1 Is a Novel Phosphorylated Tau Binding Protein That Accumulates in Alzheimer’s Disease.mp4
O4-02-01 – Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial.mp4
O4-02-02 – What Are the Effects of Benzodiazepine and Anticholinergic Drug Use on the Brain- Neuropathological Study.mp4
O4-02-03 – Randomized Trial of Suvorexant for Treating Insomnia in Alzheimer’s Disease Effects on Objective Sleep Measures.mp4
O4-02-04 – Exploring Gut Microbiota As a Source of Potential Biomarkers Initial Results from the Anavex.mp4
O4-02-05 – Continued Innovations in Study Start up (SSU)Ongoing Progress of the GAP Foundation on Site Start up.mp4
O4-02-06 – Oral Treatment with RD2 Reduces AB Oligomer Load, Enhances Cognition, Decelerates.mp4
O4-03-01 – Frontotemporal Lobar Degeneration Research in North AmericaProgress in the ArtflLefftds Consortia.mp4
O4-03-02 – Differentiating Frontotemporal Dementia from Alzheimer’s Disease on Measures of Empathy.mp4
O4-03-03 – Clinical Characterization of Mild Cognitive Impairment Associated with Eventual Lewy Body Disease Pathology.mp4
O4-03-04 – Profile of and Risk Factors for Post-Stroke Cognitive Impairment in Diverse Ethno-Regional Groups.mp4
O4-03-05 – Longitudinal Cognitive Decline and Prodromal Staging Model for Alzheimer’s Disease in Down Syndrome.mp4
O4-03-06 – Longitudinal Association between Apathy and Cognitive Decline.mp4
O4-04-01 – What Can Structural MRI Tell about aTN Staging.mp4
O4-04-02 – Identification of Fast Converters Among MCI Patients By Integrating Incomplete.mp4
O4-04-03 – The Biological Basis of Cognitive Impairment Due.mp4
O4-04-04 – Pib(+) Chronicity Provides Unique Information about Cognitive Decline and NFT Development.mp4
O4-04-05 – Microglial Activation and Tau Burden Predict Cognitive Decline in Alzheimer’s Disease.mp4
O4-04-06 – Amyloid PET Is More Than Just Positive or Negative Amyloid Level Impacts Risk of Clinical Progression in Normal Individuals..mp4
O4-05-01 – Apolipoprotein e4 Allele Effects on Longitudinal Cognitive Trajectories Are Sex- and Age-Dependent.mp4
O4-05-02 – Does the Effect of Education on Cognition Differ across RacialEthnic Groups Evidence from the Kaiser Healthy Aging.mp4
O4-05-03 – A Longitudinal Study of the Effects of Education and Intracranial Volume.mp4
O4-05-04 – Subclinical Cardiovascular Dysfunction Is Associated with Increased Cerebrospinal Fluid ….mp4
O4-05-05 – Social Support and Cognitive Function in Type 1 Diabetes Findings from the Study of Longevity in Diabetes (SOLID) Study.mp4
O4-05-06 – Invariance Measurement of Neuropsychological Tests across Different Sociodemographic Background.mp4
O4-06-02 – Fitness for the Ageing Brain Study (FABS) Long-Term Follow-up Stage 1.mp4
O4-06-03 – Exploring Individual Variability in Exercise-Induced Cognitive Change.mp4
O4-06-04 – Precision Medicine Intervention in Patients at Risk for Alzheimer’s Dementia.mp4
O4-06-05 – Promoting a Brain-Healthy Lifestyle for Reducing the Risk of Cognitive Decline and Dementia Libra and the Mijnbreincoach.mp4
O4-06-06 – An Evaluation of the Implementation of Mybrainrobbie in School-Age Children in France.mp4
O4-07-01 – Trends in Dementia Prevalence, Incidence and Mortality in the United States.mp4
O4-07-02 – Trends in Incident Dementia and Early Life Environment By Birth Cohort.mp4
O4-07-03 – Birth Cohort Analysis of Trends in Amnestic Mild Cognitive Impairment (MCI).mp4
O4-07-04 – Subjective Cognitive Decline Higher Among Sexual and Gender Minorities Population-Based Findings from Nine States in the U.S..mp4
O4-07-05 – NIA-AA Research Framework Application to the French Population By Inference from the Memento Cohort.mp4
O4-08-01 – Unmet Needs Among Americans Living Alone with Dementia A Population-Based Study.mp4
O4-08-02 – Priorities and Concerns of Older Latinos Living Alone with Cognitive Impairment An in-Depth Perspective.mp4
O4-08-03 – Village Infrastructure, Community Facilities and Its Effect on Cognitive Function Among Older Adults in Rural China Evidence from the Baseline.mp4
O4-08-04 – Where Do I Fit in the Impact of Gentrification on Aging in Place.mp4
O4-08-05 – Well-Being and Quality of Life in Mild Cognitive Impairment The Influence of Social Networks, Loneliness and Spirituality.mp4
O4-08-06 – Neighborhood Park Space and Cognition in Non-Demented Older Adults The Multi-Ethnic Study of Atherosclerosis.mp4
O4-09-01 – Leveraging Mouse Genetic Diversity to Investigate the Role of Brain Myeloid Cells in Alzheimer’s Disease.mp4
O4-09-02 – Regulation of Pro-Inflammatory and Disease-Associated Microglial Activation By Bin1.mp4
O4-09-03 – Immunosuppression Exacerbates Alzheimer’s Disease Pathology in APP PS1 Transgenic Mice.mp4
O4-09-04 – Upregulation of SOCS3 By Aspirin in Brain Cells Via PPAR-Alpha.mp4
O4-09-05 – Inteleukin-10 Induces Metabolic Changes Driving Aá Immune Tolerance in Macrophages.mp4
O4-09-06 – Clonally Expanded CD8 T Cells Patrol Alzheimer’s Cerebrospinal Fluid.mp4
O4-10-01 – Characterizing Cell Type-Specific Expression Signatures in Brain Using Single Cell RNA Sequencing.mp4
O4-10-02 – Dysregulated Fc Gamma R-Mediated Phagocytosis Pathway in Alzheimer’s Disease Network-Based Gene Expression Analysis.mp4
O4-10-03 – Functional Dissection of Alzheimer’s Disease Brain Gene Expression Signatures in Humans and Mouse Models.mp4
O4-10-04 – Large-Scale Proteomic Analysis of Human Prefrontal Cortex Identifies Proteins Associated with Cognitive Trajectory in Advanced Age.mp4
O4-10-05 – Multi-Omic Analysis Identifies Transcriptional Networks and Drivers Associated with Cognitive Aging and Alzheimer’s Disease.mp4
O4-10-06 – Integrated Genetic-Epigenetic Analyses of Alzheimer’s Disease.mp4
O4-11-01 – World Wide Fingers A Global Collaboration for Future Generations.mp4
O4-11-02 – NSAIDs for AD Prevention Naproxen Enters the CNS without Apparent Effect on CSF Immune Markers.mp4
O4-11-03 – U.S. Pointer Study Design and Launch.mp4
O4-11-04 – Linking Diabetes and Alzheimer’s Disease through RAGE. a Retrospective Analysis of Azeliragon Phase 2 and Phase 3 Studies.mp4
O4-11-05 – A Proof of Concept Phase II Study Repurposing Atomoxetine for Neuroprotection in Mild Cognitive Impairment Evidence.mp4
O4-11-06 – Defining Cognition in Pre-Dementia Clinical Trials Baseline Neuropsychological Data from the TOMMORROW Study.mp4
O4-12-01 – Tau PET Imaging Correlates with Neuropathology.mp4
O4-12-02 – Tau Pathology and Cognition Are Related to Basal Forebrain Degeneration in Aging.mp4
O4-12-03 – Cortical Tau Deposition Follows Patterns of Entorhinal Functional Connectivity in Cognitively Normal Older Adults.mp4
O4-12-04 – Cerebrospinal Fluid and PET Measures of Tau Pathology Indicate Different State of AD Pathophysiological Progression.mp4
O4-12-05 – Evaluation of Tau Deposition in Amyloid Positive MCI or Mild-AD Dementia Subjects from the Elenbecestat Mission AD Program.mp4
O4-12-06 – Automated Reporting of Tau PET Quantification on Brain Surface.mp4
O4-13-01 – Early Adulthood Vascular Risk Strongly Predicts Brain Volumes and White Matter Disease, but Not Amyloid Status, at Age 69-71 Year.mp4
O4-13-02 – Mid- and Late-Life Physical Activity and Brain Amyloid Deposition The Atherosclerosis Risk in Communities (ARIC)-PET Study.mp4
O4-13-03 – Plasma Amyloid-á Monomers and the Risk of Clinical Cardiovascular Disease in the General Population The Rotterdam Study.mp4
O4-13-04 – The Association between Particulate Matter and Episodic Memory Decline Is Partially Mediated By Early Neuroanatomic Biomarkers.mp4
O4-13-05 – Brain Correlates of Air Pollution in Cognitively Healthy Individuals at Risk of Alzheimer’s Disease.mp4
O4-13-06 – Associations between Multimorbidity and CSF Amyloid Cross-Sectional Analysis of the European Prevention of Alzheimer’s Dementia.mp4
O5-01-01 – Head-to-Head In Vivo Comparison of Tau Positron Emission Tomography Ligands 18f-Flortaucipir and 18f-RO948.mp4
O5-01-02 – Functional Brain Architecture Predicts Longitudinal Tau Spreading in Alzheimer’s Disease.mp4
O5-01-03 – Early Tau PET Pathology Is Associated with Memory Performance in Cognitively Unimpaired Individuals with SCD The Science Project.mp4
O5-01-04 – Patterns of Tau Pathology Identified with 18f-MK-6240 PET Imaging.mp4
O5-01-05 – Tau Imaging with 18f-MK6240 in Alzheimer’s Disease and Other Dementias.mp4
O5-01-06 – Early Tau Detection and Implications for Disease Progression.mp4
O5-02-01 – Genome-Wide Association Study of Plasma Tau Levels Using Hrc Imputations in the Framingham Study.mp4
O5-02-02 – Differential Expression of Polygenic Risk in Cerebrospinal Fluid Proteomic Measures in Alzheimer’s Disease.mp4
O5-02-03 – Onset Age Modifier for GRN-Associated Frontotemporal Lobar Degeneration.mp4
O5-02-04 – Integrative Genomic Profiling to Identify Genes and Pathways Associated with Vascular Risk in AD..mp4
O5-02-05 – Genome-Wide, Stage-Specific Association across Alzheimer’s Disease Endophenotypes Modeling SNP By Diagnosis Interactions.mp4
O5-02-06 – Genetic Association and Characterization of CCRL2-V180M with Alzheimer’s Disease, Cognitive Decline, and Serum Cytokine Levels..mp4
O5-03-01 – Affordable EEG Markers for the Screening of Cognitive Impairment of Old Adults.mp4
O5-03-02 – Electroretinography in Pre-Clinical Alzheimer’s Disease An Electrophysiologic Assessment of the Retina As an Early Detection Ocular.mp4
O5-03-03 – The Subclinical-Clinical Spectrum of Hyperexcitability in Alzheimer’s Disease An Ambulatory Scalp EEG Study.mp4
O5-03-04 – Abnormalities of Electroencephalographic (EEG) Markers in Quiet Wakefulness Are Related to Motor Deficits, Cognitive Symptoms.mp4
O5-03-05 – Retinal Nerve Fiber Layer Thinning in Pre-Clinical Alzheimer’s Disease Predicts CSF Amyloid Tau Classification.mp4
O5-03-06 – Do Odor Identification and Remote Odor Memory Together Predict Conversion from MCI to AD in ApoE e4 Carriers.mp4
O5-04-01 – TRIM46 Knockdown Causes Neuronal Tau Redistribution and Increases Axosomatic Tau Diffusion.mp4
O5-04-02 – Traumatic Brain Injury Induces Tau Aggregation and Spreading.mp4
O5-04-03 – Relevance of Tau Seeding for the Clinical Heterogeneity of Alzheimer’s Disease, Implication for Therapeutic Perspectives.mp4
O5-04-04 – Accumulation of Modifications in the Tau Core Region during the Tau Aggregation Process in Alzheimer’s Disease.mp4
O5-04-05 – A New Therapeutic Strategy for Tauopathies- Discovery of Highly Potent Brain Penetrant PROTACTM Degrader Molecules That Target.mp4
O5-04-06 – Tau Associates with Ribosomal Proteins Shifting the Translatome.mp4
O5-05-01 – Multivariate Patterns of Association between Diffusion Imaging Metrics and Plasma Neurofilament Light in Prodromal Alzheimer’s Disease.mp4
O5-05-02 – CSF Biomarkers of Synaptic Damage (Neurogranin, SNAP25) and Interneuron-Dependent Synaptic Homeostasis (NPTX2)I.mp4
O5-05-03 – Associations between Cerebrospinal Fluid Neurodegenerative Markers Neurofilament-Light and Total Tau and Cerebrovascular Imaging Markers.mp4
O5-05-04 – Plasma Neurofilament Light Measurements in More Than 2,100 Presenilin-1 E280A Mutation Carriers and Non-Carriers from the World’s.mp4
O5-05-05 – Undulations of the Plasma Proteome Define Distinct Stages of Human Lifespan and Reveal Accelerated Aging in Alzheimer’s Disease.mp4
O5-06-01 – Selective Targeting of Amyloid-Beta Oligomer Species By PMN310, a Monoclonal Antibody Rationally Designed for Greater Therapeutic Potency.mp4
O5-06-02 – Axonal Organization Defects in the Hippocampus of Adult Conditional BACE1 Knockout Mice Implications for BACE1 Inhibitor Clinical Trials.mp4
O5-06-03 – Small Molecules Targeting Tau Aggregation Decrease Tau Pathology and Neuroinflammation In Vivo.mp4
O5-06-04 – Characterization of Novel Tau-Specific Antibodies and Enhancement of Their Delivery into the Brain Using Focused Scanning Ultrasound.mp4
O5-06-05 – Improved Intrathecal Vector Delivery for Gene Therapy in Alzheimer’s Disease.mp4
O5-06-06 – Ligands of the Core Acetylcholine Biosynthesizing Enzyme, Choline Acetyltransferase As Novel and Potential Therapeutic Agents.mp4
O5-07-01 – Global Cortical [F18]Flortaucipir Association with the Top 20 Alzheimer’s Disease Risk Genes.mp4
O5-07-02 – Apolipoprotein E and BIN1 Polymorphisms Differentially Affect Cortical Amyloid and Tau Load in Healthy Older Adults.mp4
O5-07-03 – Integrating Genetics and Brain Imaging to Improve Alzheimer’s Disease Risk Prediction.mp4
O5-07-04 – Combining Omics and Imaging Data from the Insight Pre-AD Study, Artificial Intelligence Technology Identifies Genomic.mp4
O5-07-05 – GWAS of Hippocampal Subfield and Neighboring Cortical Structure Volumes Identifies an ERC1 Locus Using ADNI High-Resolution MRI Data.mp4
O5-07-06 – The Heritability of Amyloid Deposition and Its Shared Genetic Basis with Small Vessel Disease in the Brains of Older People.mp4
O5-08-01 – Trends in Racial and Ethnic Differences in Dementia Prevalence Rates and Disease Awareness.mp4
O5-08-02 – Costs of Alzheimer’s Disease and Dementia in 188 Countries.mp4
O5-08-03 – Trajectories of Health System Use and Survival for Community-Dwelling Persons with Dementia An Inception Cohort Study.mp4
O5-08-04 – A New Open-Source Modeling Framework to Assess Cost Effectiveness of Early Intervention in Alzheimer’s Disease..mp4
O5-08-05 – Structural Uncertainty and Cross-Validation of Decision Models in the AD Setting Answering Questions from Policy Makers on the Reliability.mp4
O5-08-06 – Cost-Effectiveness of a Collaborative Dementia Care Management – Results of a Cluster-Randomized Controlled Trial.mp4
O5-09-01 – Gender Differences in Mental Status Trajectories across Adulthood Are Men More Resilient Than Women.mp4
O5-09-02 – Duration of Dementia and Formal Care Use Effects of Age, Gender, Living Situation, Dementia Medication and Ethnicity.mp4
O5-09-03 – Sex Differences in Dementia Evidence from Population-Based Studies and the Finger Lifestyle Intervention.mp4
O5-09-04 – Validity of Algorithmic Diagnoses of Dementia A Case Study of Application to Research on Race Ethnic Disparities in Dementia.mp4
O5-09-05 – Racial and Ethnic Differences in Dementia Diagnosis Following Cognitive Decline Insights from Linked Survey and Health Care Claims Data.mp4
O5-09-06 – Race Modifies the Association between Sleep Disturbance, Cognitive Decline and Alzheimer’s Disease Biomarkers Among Cognitively.mp4
O5-10-01 – Enhanced Function of PLCg2 Variant P522R in Macrophages and Microglia Is Associated with Protection from Alzheimer’s Disease.mp4
O5-10-02 – The Transcriptional Landscape of Microglial Genes in Aging and Neurodegenerative Disease.mp4
O5-10-03 – Mapping Genome Repair Hotspots in Post-Mitotic Human Neurons.mp4
O5-10-04 – Dysregulation of NSUN2 Promotes Pathological Tau Alterations in Alzheimer’s Disease.mp4
O5-10-05 – Novel Insights of Tau RNA-Protein Biology in the Precipitating Role of Chronic Stress on Alzheimer’s Disease Brain Pathology..mp4
O5-10-06 – Loss of Neuroprotective MiR-219 Reveals a Dysregulated Tau Kinase Network in Alzheimer’s Disease.mp4
PL-01-01 – Plenary Session Association Welcome.mp4
PL-01-02-01 – Understanding the Earliest Phases of Alzheimer’s Disease.mp4
PL-03-01 – Plenary Session Inge Grundke-Iqbal Award for Alzheimer’s Research Neurotoxic Reactive Astrocytes Are Induced.mp4
PL-04-01-01 – Imaging Neurodegeneration with MRI What Is New.mp4
PL-04-02-01 – The Cellular Phase of Alzheimer’s Disease.mp4
S1-01-01 – Dementia Prevention Programs in Urban and Regional Aboriginal Communities in Australia.mp4
S1-01-02 – Health Literacy and Access to Dementia Care.mp4
S1-01-03 – Improving the Lives of People with Dementia The OECD Perspective.mp4
S1-01-04 – Dementia As Access Barrier in Palliative Care.mp4
S1-02-01 – Clustering of Rare Variants in Alzheimer Disease and Related Disorders in the Colombian Population A Genomic Study.mp4
S1-02-02 – The Potential Contribution of Rare Variants to Neurodegenerative Brain Dementia.mp4
S1-02-03 – Whole-Exome Sequencing in 20,197 Persons for Rare Variants in Alzheimer’s Disease.mp4
S1-02-04 – High-Throughput Identification of Noncoding Functional SNPs.mp4
S2-01-01 – PET Markers of Microglia.mp4
S2-01-02 – PET Markers of Astrocytes.mp4
S2-01-03 – Neuroinflammation CSF Perspective.mp4
S2-01-04 – Fluid Biomarkers of Neuroinflammation.mp4
S2-02-01 – Precision Medicine Model for Targeted NSAID Therapy in AD.mp4
S2-02-03 – Insulin-Resistant Sub-Typing.mp4
S2-02-04 – Subtyping of Clinical Subjects through Exosome Analyses.mp4
S3-01-01 – Alzheimer’s and Vascular Disease A Pathobiological Perspective.mp4
S3-01-02 – Alzheimer’s Disease and Subcortical Vascular Cognitive Impairment (SVCI) Biomarker Perspective.mp4
S3-01-03 – Alzheimer’s and Lewy Body Disease Pathologic Perspective.mp4
S3-01-04 – Alzheimer’s and Lewy Body Disease Biomarker Perspective.mp4
S3-02-01 – Statistical Challenges with Responder Analysis in Exploratory Settings.mp4
S3-02-02 – Multi-Crossover Randomized Control Design Approaches Based on Analyses of ResponderNon-Responder Outcomes.mp4
S3-02-03 – Statistical Considerations for Efficient Designs within a Platform Trial Approach.mp4
S3-02-04 – Determining Whether Identification of a Responder Sub-Group is Truly Hypothesis Generating.mp4
S4-01-01 – ?Identifying Elders at risk for Cognitive Decline using the Brain Health Registry BHR.mp4
S4-01-02 – The Dutch Brain Health Registry for Recruitment of Research Participants.mp4
S4-01-03 – Swedish Clinical Quality Registry for Dementia.mp4
S4-01-04 – The Australian Dementia Network (ADNet) Clinical Quality Registry.mp4
S5-01-01 – Description and Impact of Delirium on Dementia.mp4
S5-01-01 – Immunotherapy in Alzheimer Disease Mechanisms of Monoclonal Antibodies in Development.mp4
S5-01-02 – Biomarkers in Delirium.mp4
S5-01-03 – Neurobiology of Delirium and Its Intersection with Dementia Insights from Animal Models.mp4
S5-01-04 – Systemic Inflammation Signaling to the Brain.mp4
TD-03-01 – Gait Impairments in Dementia Subtypes Considering the Impact of Environmental Context.mp4
TD-03-03 – Developing an Electronic Consent for ADRC.mp4
TD-03-04 – High Compliance, Continuous Long-Term Home Monitoring of Sleep Activity in Diverse Populations.mp4
TD-04-01 – Mobile Monitoring of Cognition in Middle-Aged and Older Adults with and without Amnestic Mild Cognitive Impairment.mp4
TD-04-04 – Augmented Reality Technology for People with Dementia.mp4
TD-04-05 – A Cross-Comparison and Validation of Four Computer-Administered Neuropsychological Assessment.mp4
TD-04-06 – Gamechanger Can Digital Biomarkers Transform the Detection of Preclinical Alzheimer’s Disease.mp4
TD-04-07 – Identifying Prodromal Features of Dementia in UK Primary Care A Nested Case-Control Study.mp4
TD-04-08 – GENFI Ignite A Novel Cognitive Assessment App for Testing Presymptomatic Frontotemporal Dementia.mp4
TD-04-09 – AI-Based Digital Phenotyping of Behavioral and Psychiatric Symptoms in Dementia Clinical Implications.mp4
TD-04-10 – Development and Usability of ADappt – an Online Tool to Support Clinicians, Patients and Caregivers.mp4
TD-04-11 – Delivering Disease Progression Models to Clinical Practice A User Study on Opportunities and Barriers for Translation and Adoption.mp4
TD-04-12 – Identifying Individuals with Dementia, MCI and Physical Impairment during Group Activities.mp4
TD-04-13 – Using Participatory Design & Community Engagement to Develop Online Caregiver Support.mp4
TD-04-14 – The Challenges of Monitoring Subject Adherence to Study Protocols in Technology-Based Aging and Dementia Clinical Research Studies.mp4
TD-04-15 – Unobtrusive, Sensor-Based Measurement of in-Home Walking Speed and Its Day-to-Day Variability Identifies Future Falls in Older Adults.mp4


There are no reviews yet.

Be the first to review “Alzheimer’s Association International Conference 2019”

Your email address will not be published.